Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) in partnership with NETRF is proud to announce Dr. Carolin Kitzberger of TUM
The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging agent may deliver clearer and more comprehensive scans for people
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and
Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and produced clinically meaningful benefits for
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others
We’re proud to celebrate Dr. Suzann Duan, an Assistant Professor in the Department of Pharmaceutical Sciences at UC Irvine, as the recipient of the 2025 Basic/Translational
By Anna Greene, PhD, NETRF Director of Research Dr. Benjamin Viglianti, recipient of a 2023 NETRF Investigator Award, is the senior author of a newly
NETRF is excited to announce that applications are now open for the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs), developed in partnership with